This move is archived. Current quotes and coverage live on the stock page.
Follow GILD
Gilead Sciences Inc. is experiencing a positive surge in its stock price following a significant legal victory.
Gilead Sciences Inc. (NASDAQ:GILD) is rising today, with shares up 1.48% to close at CA$145.84. This uptick follows a recent court ruling that has provided the company with a favorable legal standing regarding its HIV medication, Biktarvy.
Investor takeaway: The recent court ruling has removed a significant risk for Gilead, preserving its revenue from Biktarvy and potentially stabilizing its market position against cheaper imports.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$190.38B
Div. yield
2.18%
Div. / share
$3.22
52W high
$160.51
52W low
$111.27
1W change
+6.98%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 16, 2026
Wall Street analysts forecast GILD stock price to rise 403.2% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$159.58
+403.2% Upside
Previously C$159.62 on Oct 14, 2026
Current Price
C$31.71
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
23.9%
Annualized
90-Day Vol
28.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$188.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$167.02 | C$153.78 – C$181.41 |
| 60 trading days | C$177.27 | C$157.72 – C$199.24 |
| 90 trading days | C$188.14 | C$163.05 – C$217.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.48% increase in Gilead's stock price today
The stock's rise reflects investor confidence following the favorable court ruling regarding its HIV drug.
Bull case
The court's decision strengthens Gilead's ability to set prices and protects its revenue from Biktarvy, which is essential for the company's financial health.
Bear case
Even with this legal win, Gilead may still face challenges to its profitability due to ongoing pricing pressures in the pharmaceutical industry.
Advertisement
Legal Victory Bolsters Gilead's Position
Gilead's recent win in the appeals court is a significant milestone, as it upholds a preliminary injunction that prevents the importation of foreign versions of its HIV drug, Biktarvy. This ruling asserts that the U.S. version of the medication differs materially from its foreign counterparts, which is critical in maintaining Gilead's market share and pricing strategy.
Market Reactions and Future Outlook
The positive reaction in Gilead's stock price indicates that investors are optimistic about the company's ability to maintain its revenue streams. However, analysts caution that while this ruling is a win, ongoing pressures from the broader pharmaceutical market could still impact Gilead's long-term profitability. Investors will need to monitor how the company navigates these challenges moving forward.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
